Type 2 diabetes mellitus
Conditions
Interventions
Ipragliflozin
Sponsors
A society for the study of SGLT2 in Aomori-ken
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with type 2 diabetes mellitus 2) Patients with not enough blood glucose control (HbA1c > 7.0%) even if putting dietary therapy, exercise, education for improvement of a daily habit, and medicinal treatment into practice
Exclusion criteria
Exclusion criteria: 1) Patients with allergy for Ipragliflozin 2) Patients got severe ketosis, diabetic coma, and diabetic precoma during the past 6 months 3) Patients with severe infectious disease and injury, and in perioperative 4) Patients with renal dysfunction at a moderate level or high 5) Patients whose doctor judges to unfit for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We investigate HbA1c, GA, body weight, waist circumstance, body composition, and appearance of harmful phenomenon at initial and screening visits (3 month, 6 month, and 12 month after taking Ipragliflozin). | — |
Secondary
| Measure | Time frame |
|---|---|
| We investigate the dietary intake and contents at initial and screening visits (3 month, 6 month, and 12 month after taking Ipragliflozin). | — |
Countries
Japan
Contacts
Public ContactMurakami Hiroshi
Hirosaki University Graduate School of Medicine Endocrinology and Metabolism
Outcome results
None listed